GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-11-16 08:30 |
GENFIT : Information financière du troisième trimestre 2020 et lancement de la …
|
French | 199.0 KB | ||
| 2020-09-30 23:00 |
rapport semestriel 2020
|
French | 3.0 MB | ||
| 2020-09-30 22:05 |
GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy
|
English | 498.8 KB | ||
| 2020-09-30 22:05 |
GENFIT présente ses résultats financiers du premier semestre 2020 et sa nouvell…
|
French | 539.7 KB | ||
| 2020-09-28 08:00 |
GENFIT et LabCorp signent un accord exclusif pour la commercialisation d’un nou…
|
French | 190.1 KB | ||
| 2020-09-28 08:00 |
GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic…
|
English | 217.1 KB | ||
| 2020-09-24 22:10 |
GENFIT annonce la première visite du premier patient pour son essai clinique de…
|
French | 137.1 KB | ||
| 2020-09-24 22:10 |
GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating…
|
English | 129.8 KB | ||
| 2020-09-22 22:10 |
GENFIT To Announce First Half-Year 2020 Financial Results and New Corporate Str…
|
English | 84.2 KB | ||
| 2020-09-22 22:10 |
GENFIT annoncera les résultats financiers du 1er semestre 2020 et la nouvelle o…
|
French | 88.0 KB | ||
| 2020-08-26 22:10 |
GENFIT Announces Two Oral Presentations at the Digital International Liver Cong…
|
English | 282.9 KB | ||
| 2020-08-26 22:10 |
GENFIT annonce deux présentations orales au Congrès Digital International Liver…
|
French | 304.0 KB | ||
| 2020-08-05 08:30 |
GENFIT : La technologie NIS4™ objet d’une publication dans The Lancet Gastroent…
|
French | 396.8 KB | ||
| 2020-08-05 08:30 |
GENFIT Announces Pivotal Publication of NIS4™ Technology to Identify Patients w…
|
English | 274.0 KB | ||
| 2020-07-22 22:05 |
GENFIT: Provides Initial Update on Corporate Strategy
|
English | 384.1 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
